Assignee
BIOVERATIV THERAPEUTICS INC
US·69 granted patents·67 pending applications·296 citations·filing 2013–2025
Top patents by PatentIndex Score
136 records- 0198US9867873B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Jan 16, 2018·17 cites·25 claims
- 0298US9675676B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Jun 13, 2017·19 cites·30 claims
- 0398US9629903B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·17 cites·29 claims
- 0498US9623091B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Apr 18, 2017·16 cites·28 claims
- 0597US10898554B1Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 26, 2021·6 cites·22 claims
- 0696US10568943B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Feb 25, 2020·6 cites·18 claims
- 0795US11642398B2Factor IX polypeptide formulationsBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted May 9, 2023·4 cites·19 claims
- 0895US10548954B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·5 cites·16 claims
- 0995US9636416B2Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted May 2, 2017·20 cites·22 claims
- 1094US11266720B2Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 8, 2022·6 cites·64 claims
- 1194US10138291B2Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Nov 27, 2018·30 cites·36 claims
- 1293US11192936B2Factor VIII chimeric proteins and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Dec 7, 2021·10 cites·58 claims
- 1393US11091534B2Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Aug 17, 2021·8 cites·20 claims
- 1493US10881742B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·5 cites·26 claims
- 1593US10561714B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·3 cites·20 claims
- 1691US10370431B2Optimized factor VIII geneBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Aug 6, 2019·6 cites·16 claims
- 1791US10023628B2Cell line expressing single chain factor VIII polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jul 17, 2018·6 cites·17 claims
- 1890US11286528B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 29, 2022·4 cites·14 claims
- 1990US11008561B2Optimized factor IX geneBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted May 18, 2021·4 cites·22 claims
- 2090US9725496B1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Aug 8, 2017·4 cites·27 claims
- 2189US10745680B2Factor IX fusion proteins and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·6 cites·27 claims
- 2289US10548953B2Factor VIII-XTEN fusions and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Feb 4, 2020·6 cites·17 claims
- 2389US10001495B2Blood factor monitoring assay and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jun 19, 2018·6 cites·22 claims
- 2488US12186375B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 7, 2025·1 cites·19 claims
- 2588US11370827B2Chimeric factor VIII polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jun 28, 2022·5 cites·48 claims
- 2688US11225650B2Methods of using FIX polypeptidesBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Jan 18, 2022·5 cites·20 claims
- 2787US11753461B2Optimized factor VIII genesBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Sep 12, 2023·3 cites·15 claims
- 2887US11168125B2Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Nov 9, 2021·1 cites·10 claims
- 2987US10786554B2Factor VIII polypeptide formulationsBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Sep 29, 2020·5 cites·42 claims
- 3086US12275970B2Optimized factor IX geneBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Apr 15, 2025·1 cites·15 claims
- 3186US10588949B2Factor IX polypeptide formulationsBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Mar 17, 2020·8 cites·42 claims
- 3286US2025195620A1Factor viii chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3384US2023023927A1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3483US11787851B2Optimized factor VIII geneBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Oct 17, 2023·1 cites·12 claims
- 3583US10058480B2Device containerBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Aug 28, 2018·10 cites·21 claims
- 3682US10221455B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Mar 5, 2019·5 cites·25 claims
- 3782US2025136640A1On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3882US2024212861A1Population pharmacokinetics tools and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3982US2022010000A1Immunoglobulin chimeric monomer-dimer hybridsBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4081US11578098B2On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Feb 14, 2023·1 cites·20 claims
- 4181US11372008B2Blood factor monitoring assay and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Jun 28, 2022·1 cites·9 claims
- 4281US10927362B2Processable single chain molecules and polypeptides made using sameBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Feb 23, 2021·1 cites·14 claims
- 4381US10287564B2Procoagulant compoundsBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted May 14, 2019·5 cites·11 claims
- 4480US12134632B2On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2023·Granted Nov 5, 2024·0 cites·21 claims
- 4580US10391152B2Methods of using a fixed dose of a clotting factorBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Aug 27, 2019·5 cites·14 claims
- 4680US2024141019A1Optimized factor viii geneBIOVERATIV THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4779US10772942B2Lyophilized factor IX formulationsBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Sep 15, 2020·5 cites·10 claims
- 4878US10370430B2Recombinant factor VIII proteinsBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Aug 6, 2019·3 cites·20 claims
- 4978US2021277378A1Coagulation factor ix compositions and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5077US10611794B2On-column viral inactivation methodsBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Apr 7, 2020·2 cites·41 claims
Showing the top 50 of 136 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →